This year’s State of the Industry focused on the year ahead.
We changed our annual State of the Industry survey this year. In the past, many of our questions looked back at developments in the past year. We published the results in the December issue.
This year we pivoted and asked questions about the year ahead instead of the year gone by. And it makes more sense to publish the results of a forward-looking survey in January.
We had exactly 100 respondents, although not every respondent answered every question. About one-quarter of the respondents said they worked for hospitals and healthcare systems. A similar proportion indicated that they worked for physician groups. The rest were evenly divided among health plans, consulting firms and other sorts of healthcare companies.
We will be posting results of the survey.
Our first question was a general one: Which will be the most important issues facing American healthcare in the 2022. We gave the respondents eight choices and asked them to rank them on the scale of 1 to 10, with 10 indicating the highest importance. We then summed the rankings, assigning a value of 10 to ranking, a value of 9 to ranking of 9, and so on.
Using this metric for importance, consolidation and labor shortages came out on top, followed by high drug prices, supply chain issues and COVID-19 vaccination rates.
Our survey circulated prior to the peaking of the omicron variant. Perhaps COVID-19 vaccination rates would have ranked higher if people were filling out the survey now.
Premiums for Employer-based Health Insurance Increased by 7% in 2024, Says KFF Report
Published: October 9th 2024 | Updated: October 9th 2024The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Listen
Parity for Mental Health — Any Progress?
October 12th 2023Laws since 1996 have sought to assure that coverage of behavioral health treatments does not take a back seat to physical medicine. Amid a national crisis in mental illness and addiction, that new world of equality has not arrived. But is it on the way?
Read More